Search

Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013

Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.

Read more

Celebrating the International Day of Women & Girls in Science

On this International Day of Women & Girls in Science, we take a moment to honor, appreciate and thank, all the women scientists at the forefront of the fight against COVID-19.

Read more

Social Media Learning

EHA presents our own microlearning in 4 formats, covering diagnosis, pathology, clinical schemas, and clinical cases within topics in the European Hematology Curriculum.

Read more

Publications

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Leuk Res. 2017 Oct;61:6-9. doi: 10. 1016/j. leukres. 2017. 08. 002.

Read more

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Read more

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

Read more

How to apply for an EHA Research Grant

On this page, we explain all of the actions you'll need to take when submitting a grant application. You can also get a basic overview of the process in our EHA Research Grants diagram.

Read more

How to apply for an EHA Innovation Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Innovation Grant application.

Read more